Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Kober, Kord Michael

University Of California, San Francisco
United States

An Investigation of the Molecular Mechanisms for and Prediction of the Severity of Cancer Chemotherapy-Related Fatigue Using a Multi-staged Integrated Omics Approach 5R37CA233774-07 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Kolb, Noah Allan

University Of Vermont & St Agric College
United States

Remote Monitoring of Management of Chemotherapy induced Peripheral Neuropathy 5R01CA247517-05 Brennan Streck, Ph.D., RN, M.P.H.
Kolb, Noah Allan

University Of Vermont & St Agric College
United States

Remote Monitoring of Management of Chemotherapy induced Peripheral Neuropathy 5R01CA247517-05 Brennan Streck, Ph.D., RN, M.P.H.
Kong, Mei

University Of California-Irvine
United States

Using dietary glutamine supplementation for melanoma prevention and targeted therapy 5R01CA244360-05 Gabriela Riscuta, M.D., CNS
Kooperberg, Charles L

Fred Hutchinson Cancer Center
United States

Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) 5UG1CA287013-02 Elyse LeeVan, M.D., M.P.H.
Kresty, Laura A

University Of Michigan At Ann Arbor
United States

Developing Natural Products to Target IL-8 Signaling and Intercept Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma 1UG3CA299397-01 Altaf Mohammed, Ph.D.
Krist, Alexander H

Virginia Commonwealth University
United States

Virginia Cancer Screening Research Network Access Hub (Virginia CSRN Hub) 3UG1CA287017-02S1 Elyse LeeVan, M.D., M.P.H.
Kroetz, Deanna L

Ohio State University
United States

Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity 5R01CA261068-06 Rachel Altshuler, Ph.D.
Kroetz, Deanna L

Ohio State University
United States

Sphingolipid Signaling and Chemotherapy-Induced Peripheral Neurotoxicity 5R01CA261068-06 Rachel Altshuler, Ph.D.
Kuhn, Peter

University Of Southern California
United States

Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma 4U01CA285013-03 Nicholas Hodges, Ph.D.
Kumar, Nagi B.

H. Lee Moffitt Cancer Ctr & Res Inst
United States

Phase II Clinical trial of GTC in Men on Active Surveillance 5R01CA235032-06 Howard L. Parnes, M.D.
Labaer, Joshua

Arizona State University-Tempe Campus
United States

Multiplex In-Solution Protein Array (MISPA) for high throughput, quantitative, early profiling of pathogen-induced head and neck 5R33CA281802-03 Wendy Wang, Ph.D., M.Sc.
Labaer, Joshua

Arizona State University-Tempe Campus
United States

High-throughput immunoproteomics for cancer biomarker discovery 5U2CCA271903-04 Christos Patriotis, Ph.D., M.Sc.
Lampe, Paul D.

Fred Hutchinson Cancer Center
United States

Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer 5R01CA281801-03 Guillermo Marquez, Ph.D.
Langel, Stephanie N.

Case Western Reserve University
United States

Antibody bound bacteria during HPV infection and cervical dysplasia 3R21CA289927-02S1 Goli Samimi, Ph.D., M.P.H.